Stock Ratings / Health Care / CV / insiders

ELMD (77) FOCL (29) INMD (74) HSDT (37) ⌘ Pro Terminal →

CapsoVision Inc. (CV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.94 -1.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.91

CapsoVision Inc. (CV) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $369.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.91 (-0.50%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CV)Realized 20D OHLCV Swing Band: ±9.3%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY CV SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 54 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.59-0.9% Next Q

Q2 (-2Q)

Grade E$6.53+7% Next Q

Q3 (-1Q)

Grade D$6.99-0.7% Next Q

Current

Grade D$6.94-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CV currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.42) and Max Pain ($7.29) forces dealer call-delta covering toward $16.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CV Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CV)

✓Walkthrough of CV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.98%⚡ TESTING RESISTANCE

2026-10-30O $6.99H $7.10L $6.79C $6.94VOL 86.7K

RES: $6.91SUP: $5.91SMA50: $6.42SMA200: $6.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CV Butterfly Map → + Track CV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +15.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CV)

Health Care Rank #509 of 1016 ⚔️ ELMD vs CV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CV vs. ELMD, FOCL, INMD, HSDT)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CapsoVision Inc. (CV) ranks #509 by composite RQD confidence (44/100, grade D) and #493 by equity capitalization ($369.2M). Within this direct 5-issuer industry benchmark cohort, ELMD leads on earnings valuation at 30.4x trailing P/E, while ELMD leads on capital efficiency and profitability with 24.1% ROIC and 78.1% gross margin. ELMD currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with CV at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CV ACTIVE CapsoVision Inc.	D	44/100	—	52.9%	-35.0%	-1.70%	$369.2M	Benchmark Subject
ELMD Electromed Inc.	B+	77/100	30.4x	78.1%	24.1%	+1.47%	$229.4M	/elmd-vs-cv →
FOCL EDAP TMS S.A.	E	29/100	—	42.5%	-35.0%	-2.11%	$191.6M	/focl-vs-cv →
INMD InMode Ltd.	B	74/100	—	78.5%	17.7%	+1.05%	$776.6M	/inmd-vs-cv →
HSDT Solana Company (Class A)	D-	37/100	—	96.0%	-35.0%	-1.31%	$146.5M	/hsdt-vs-cv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001378325

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CapsoVision Inc. (CV) reported GAAP revenue of $13.6M (+15.3% vs. FY2024 revenue of $11.8M ) , GAAP net income of -$25.3M, operating cash flow of -$22.9M, and free cash flow of -$23.0M (-13.4% YoY). On the balance sheet, CV closed FY2025 with $18.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.6M	-$25.3M	-$22.9M	-$23.0M	$18.2M	—
FY2024 (FY)	2024-12-31	$11.8M	-$19.9M	-$20.1M	-$20.2M	$16.8M	—

3. CV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CapsoVision Inc. (NASDAQ: CV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $6.94 (-1.70% 1D, market cap $369.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CV ranks #509 in composite RQD confidence.

How does CV compare to ELMD and FOCL in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CV carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 52.9%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a B+ grade (77/100 RQD, P/E 30.4x, ROIC 24.1%, cap $229.4M) and FOCL (EDAP TMS S.A.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $191.6M). Among the 5-stock peer group, ELMD leads on earnings multiple (30.4x) while ELMD leads on capital efficiency (24.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CV?

Per CV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001378325), CapsoVision Inc. generated $13.6M in revenue (+15.3% YoY), -$25.3M in net income, and -$23.0M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CV trading relative to its 50-day, 200-day, and 52-week technical levels?

CV last traded at $6.94 (-1.70% on volume of 101,950 shares), positioning the stock +8.10% above its 50-day simple moving average ($6.42) and +9.29% above its 200-day simple moving average ($6.35). Across its 52-week range of $4.50 to $15.37, CV sits at the 22.4% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($6.29 to $7.59).

CV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CV insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CV leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CV RQD Cockpit CV 12M Forecast CV Earnings & Move CV Dividends & DRIP CV Insiders & 13F CV Whale Options CV Profit Sankey CV News & Why